ai3Bio

Have updates for this profile? Please contribute data

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.

ai3Bio - overview

Location

-, -, US

Primary Industry

Biotechnology

About

based in Massachusetts, US, and co-founded in 2025, ai3Bio is a biotechnology company that research and develops immunology-based therapies for autoimmune diseases through its platforms use lipid nanoparticle (LNP)/mRNA and antibody technologies to identify and eliminate disease-causing T cells directly in vivo, aiming to restore immune balance at the source of disease.


Primary Industry

Biotechnology

Sub Industries

Molecular Science, Genetics & Gene Therapy, Healthcare IT

Website

www.ai3.bio

Verticals

Artificial Intelligence, HealthTech, Nanotechnology, Research (Non-Medical)

Company Stage

Series A

Total Amount Raised

Subscriber access only

GoingPro

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.